Treatment of a population based sample of men diagnosed with testicular cancer in the United States.
OBJECTIVE
Testicular cancer is the most common cancer in men age 25 to 35 years. We examined therapy, compliance with guidelines, and survival in a population based sample of men newly diagnosed with testicular cancer.


METHODS
We analyzed the National Cancer Institute's (NCI) patterns of care data on 702 men diagnosed with testicular cancer in 1999. These studies supplement routine data collection by verifying therapy with the patients' treating physicians. Follow-up for vital status was available through December 31, 2004.


RESULTS
The majority of the men with seminoma were diagnosed while their cancer was localized and more than 80% of received orchiectomy with radiation. For men with seminoma and nonseminoma germ cell tumors (NSGCT), the percent receiving chemotherapy increased markedly as stage increased. More than 90% of men with regional and distant NSGCT received chemotherapy. Less than 25% of men with localized NSGCT received orchiectomy and retroperitoneal lymph node dissection (RPLND), about 40% had surveillance following an orchiectomy alone, and 30% received orchiectomy and chemotherapy.


CONCLUSIONS
The majority of these patients received therapy consistent with guidelines. While there was no significant difference in the use of RPLND in men with localized NSGCT by geographic region, chemotherapy use varied widely. Over 90% of men with localized or regional disease diagnosed in 1999 were alive at the end of 2004. The excellent survival rates point to the need to monitor for late effects of therapy.
Osswald
Michael
M
Department of Medicine, Lackland Air Force Base, San Antonia, TX 78236, USA.
Harlan
Linda C
LC
Penson
David
D
Stevens
Jennifer L
JL
Clegg
Limin X
LX
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D018237:Germinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D019983:Guideline Adherence; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011878:Radiotherapy; D012187:Retroperitoneal Space; D018426:SEER Program; D018239:Seminoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014481:United States; D055815:Young Adult
D000970:Antineoplastic Agents
J Clin Oncol. 2005 Aug 20;23(24):5757-61
16110032
BJU Int. 2006 Jul;98(1):67-9
16831145
Urol Int. 2005;75(4):304-8
16327295
Ann Oncol. 2004 Sep;15(9):1377-99
15319245
Lancet. 2005 Jul 23-29;366(9482):293-300
16039331
Urol Oncol. 2006 Jan-Feb;24(1):68-74
16414498
J Clin Oncol. 1997 May;15(5):1844-52
9164194
Urology. 2004 Mar;63(3):556-61
15028457
Cancer. 1999 Nov 15;86(10):2171-83
10570449
J Clin Oncol. 1993 Apr;11(4):598-606
8386751
J Clin Oncol. 2000 Oct 15;18(20):3558-85
11032599
Eur J Cancer. 2006 May;42(7):820-6
16574403